vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-538Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWМЕТОТРЕКСАТ — «ЗОЛОТОЙ СТАНДАРТ» ЛЕЧЕНИЯ ЮВЕНИЛЬНОГО РЕВМАТОИДНОГО АРТРИТАMETHOTREXATE — «GOLD STANDARD» OF JUVENILE RHEUMATOID ARTHRITIS TREATMENTАлексееваЕ. И.AlekseyevaYe. I.

Контактная информация: Алексеева Екатерина Иосифовна, доктор медицинских наук, профессор, декан ФППО педиатрического факультета Первого МГМУ им. И.М. Сеченова, заведующая ревматологическим отделением Научного центра здоровья детей РАМН Адрес: 119991, Москва, Ломоносовский проспект, д. 2/62, тел.: (499) 134-02-97

neonatepearl@yandex.ruВалиеваС. И.ValiyevaS. I.neonatepearl@yandex.ruБзароваТ. М.BzarovaT. M.neonatepearl@yandex.ruДенисоваР. В.DenisovaR. V.neonatepearl@yandex.ruНаучный центр здоровья детей РАМН, Москва Первый Московский государственный университет им. И.М. СеченоваРоссияScientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow I.M. Sechenov First Moscow State Medical UniversityRussian FederationНаучный центр здоровья детей РАМН, МоскваРоссияI.M. Sechenov First Moscow State Medical UniversityRussian Federation201117012011101Вопросы современной педиатрии4249Copyright © Алексеева Е.И., Валиева С.И., Бзарова Т.М., Денисова Р.В., 20112011Алексеева Е.И., Валиева С.И., Бзарова Т.М., Денисова Р.В.Alekseyeva Y.I., Valiyeva S.I., Bzarova T.M., Denisova R.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/538

В статье представлен обзор литературы последних лет об эффективности и безопасности метотрексата в лечении ювенильного артрита. Показано, что применение меторексата в дозе 15 мг/м2 поверхности тела в неделю позволяет значительно снизить воспалительную активность ревматоидного процесса, а иногда и индуцировать клинико-лабораторную ремиссию заболевания. Для достижения максимального эффекта предпочтительно подкожное или внутримышечное введение препарата.

The article presents the literature review of recent publications on efficacy and safety of methotrexate in treatment of juvenile rheumatoid arthritis. Administration of methotrexate 15 mg/m2 of body surface weekly results in significant decrease of inflammatory activity of rheumatoid process and in several cases in induction of clinical and laboratory remission of the disease. Maximal effect can be achieved via subcutaneous or intramuscular injection.

ювенильный ревматоидный артритдетилечениеметотрексатjuvenile rheumatoid arthritischildrentreatmentmethotrexateReferencesCassidy J., Petty R. Texbook of paediatric rheumatology, 5th еd. — Elsevier Saunders, 2005.Cassidy J., Petty R. Texbook of paediatric rheumatology, 5th еd. — Elsevier Saunders, 2005.Алексеева Е. И., Литвицкий П. Ф. Ревматоидный артрит. Этиология, патогенез. Клиника. Алгоритмы диагностики и лечения. — М.: Веди, 2007. — 359 с.Алексеева Е. И., Литвицкий П. Ф. Ревматоидный артрит. Этиология, патогенез. Клиника. Алгоритмы диагностики и лечения. — М.: Веди, 2007. — 359 с.Kroot E. J. A., van Leeuwen M. A., van Rijswijk M. H. et al. No increased mortality in patient with rheumatoid arthritis: up to 10 years of follow-up from disease onset // Ann. Rheum. Dis. — 2000; 59: 954–958.Kroot E. J. A., van Leeuwen M. A., van Rijswijk M. H. et al. No increased mortality in patient with rheumatoid arthritis: up to 10 years of follow-up from disease onset // Ann. Rheum. Dis. — 2000; 59: 954–958.Kutukculer N., Caglayan S., Aydogdu F. Study of pro-inflammatory (TNF-alpha, IL-1-alpha, IL-6) and T-cell derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: Correlations with clinical and laboratory parameters // Clin. Rheumatol. — 1998; 17: 288–92.Kutukculer N., Caglayan S., Aydogdu F. Study of pro-inflammatory (TNF-alpha, IL-1-alpha, IL-6) and T-cell derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: Correlations with clinical and laboratory parameters // Clin. Rheumatol. — 1998; 17: 288–92.Mangge H., Kenzian H., Gallistl S. et al. Serum cytokines in juvenile rheumatoid arthritis: correlation with conventional inflammation parameters and clinical subtypes // Arthritis Rheum. — 1995; 38: 211–20.Mangge H., Kenzian H., Gallistl S. et al. Serum cytokines in juvenile rheumatoid arthritis: correlation with conventional inflammation parameters and clinical subtypes // Arthritis Rheum. — 1995; 38: 211–20.Клинические рекомендации. Ревматология / под ред. Е. Л. Насонова. — М.: ГЭОТАР-Медиа, 2005. — С. 25–71, 120–140.Клинические рекомендации. Ревматология / под ред. Е. Л. Насонова. — М.: ГЭОТАР-Медиа, 2005. — С. 25–71, 120–140.Fleischmann R. Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis // Expert Opin. Drug. Saf. — 2003; 2 (4): 347–365.Fleischmann R. Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis // Expert Opin. Drug. Saf. — 2003; 2 (4): 347–365.Алексеева Е. И., Шахбазян И. Е. Принципы патогенетической терапии тяжелых системных вариантов ювенильного ревматоидного артрита // Аутоиммунные болезни. — 2002; 5: 127.Алексеева Е. И., Шахбазян И. Е. Принципы патогенетической терапии тяжелых системных вариантов ювенильного ревматоидного артрита // Аутоиммунные болезни. — 2002; 5: 127.Hashkes P. J., Laxer R. M. Medical treatment of juvenile idiopathic arthritis // JAMA. — 2005; 294 (13): 1671–1684.Hashkes P. J., Laxer R. M. Medical treatment of juvenile idiopathic arthritis // JAMA. — 2005; 294 (13): 1671–1684.Насонов Е. Л. Противовоспалительная терапия ревматических болезней. — М.: М–Сити, 1996. — 345 с.Насонов Е. Л. Противовоспалительная терапия ревматических болезней. — М.: М–Сити, 1996. — 345 с.Alarcon G. S. Methotrexate: Its use for the treatment of rheumatoid arthritis and other rheumatic disorders. In Arthritis and Allied Conditions. A Text book of rheumatology, 13th Edition / еd. W. J. Koopman. — Baltimore, Philadelphia, London: Williams & Wilkins, 1997; 1: 679–98.Alarcon G. S. Methotrexate: Its use for the treatment of rheumatoid arthritis and other rheumatic disorders. In Arthritis and Allied Conditions. A Text book of rheumatology, 13th Edition / еd. W. J. Koopman. — Baltimore, Philadelphia, London: Williams & Wilkins, 1997; 1: 679–98.Cronstein B. N. The mechanism of action of methotrexate // Rheum. Dis. Clin. North. Amer. — 1997; 23: 739–755. 13. Furst D. E. The rational use of methotrexate in rheumatoid arthritis // Br. J. Rheumatol. — 1997; 36: 1196–1204.Cronstein B. N. The mechanism of action of methotrexate // Rheum. Dis. Clin. North. Amer. — 1997; 23: 739–755. 13. Furst D. E. The rational use of methotrexate in rheumatoid arthritis // Br. J. Rheumatol. — 1997; 36: 1196–1204.Bologna C., Viu P., Picot M. C. et al. Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study // Brit. J. Rheumatol. — 1997, 36: 535–540.Bologna C., Viu P., Picot M. C. et al. Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study // Brit. J. Rheumatol. — 1997, 36: 535–540.Scott D. L., Symmons D. P., Coulton B. L., Popert A. J. Long-term outcome of treating rheumatoid arthritis: results after 20 years // Lancet. — 1987; 1: 1108–1111.Scott D. L., Symmons D. P., Coulton B. L., Popert A. J. Long-term outcome of treating rheumatoid arthritis: results after 20 years // Lancet. — 1987; 1: 1108–1111.Tambic-Bukovac L., Malcic I., Prohic A. Personal experience with methotrexate in the treatment of idiopathic juvenile arthritis // Rheumatism. — 2002; 49 (1): 20–24.Tambic-Bukovac L., Malcic I., Prohic A. Personal experience with methotrexate in the treatment of idiopathic juvenile arthritis // Rheumatism. — 2002; 49 (1): 20–24.Cassidy J. T. Outcomes research in the therapeutic use of methotrexate in children with chronic peripheral arthritis // J. Pediatr. — 1998; 133: 179–180.Cassidy J. T. Outcomes research in the therapeutic use of methotrexate in children with chronic peripheral arthritis // J. Pediatr. — 1998; 133: 179–180.Ramanan A. V., Whitworth P., Baildam E. M. Use of methotrexate in juvenile idiopathic arthritis // Arch. Dis. Child. — 2003; 88: 197–200.Ramanan A. V., Whitworth P., Baildam E. M. Use of methotrexate in juvenile idiopathic arthritis // Arch. Dis. Child. — 2003; 88: 197–200.Yokota S. Classification and treatment strategy for juvenile idiopathic arthritis // Therapy. — 1999; 81: 766–772.Yokota S. Classification and treatment strategy for juvenile idiopathic arthritis // Therapy. — 1999; 81: 766–772.Giannini E. H., Brewer E. J., Kuzmina N. et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group // N. Engl. J. Med. — 1992; 326: 1043–1049.Giannini E. H., Brewer E. J., Kuzmina N. et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group // N. Engl. J. Med. — 1992; 326: 1043–1049.Woo P., Southwood T. R., Prieur A. M. et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis // Arthr. Rheum. — 2000; 43 (8): 1849–1857.Woo P., Southwood T. R., Prieur A. M. et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis // Arthr. Rheum. — 2000; 43 (8): 1849–1857.Silverman E., Mouy R., Spiegel L. et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis // N. Engl. J. Med. — 2005; 352: 1655–1666.Silverman E., Mouy R., Spiegel L. et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis // N. Engl. J. Med. — 2005; 352: 1655–1666.Ruperto N., Murray K. J., Gerloni V. et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate // Arthritis Rheum. — 2004; 50: 2191–2201.Ruperto N., Murray K. J., Gerloni V. et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate // Arthritis Rheum. — 2004; 50: 2191–2201.Tukova J., Chladek J., Nemcova D. et al. Methotrexate bioavailability after oral and subcutaneous dministration in children with juvenile idiopathic arthritis // Clin. Exp. Rheumatol. — 2009; 27 (6): 1047–1053.Tukova J., Chladek J., Nemcova D. et al. Methotrexate bioavailability after oral and subcutaneous dministration in children with juvenile idiopathic arthritis // Clin. Exp. Rheumatol. — 2009; 27 (6): 1047–1053.Alsufyani K., Ortiz-Alvarez O., Cabral D. A. et al. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate // J. Rheumatol. — 2004; 31 (1): 179–182.Alsufyani K., Ortiz-Alvarez O., Cabral D. A. et al. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate // J. Rheumatol. — 2004; 31 (1): 179–182.Ravelli A., Viola S., Migliavacca D. et al. The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis // J. Pediatr. — 1999; 135 (3): 316–20.Ravelli A., Viola S., Migliavacca D. et al. The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis // J. Pediatr. — 1999; 135 (3): 316–20.Heiligenhaus A., Mingels A., Heinz C., Ganser G. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication // Eur. J. Ophthalmol. — 2007; 17 (5): 743–748.Heiligenhaus A., Mingels A., Heinz C., Ganser G. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication // Eur. J. Ophthalmol. — 2007; 17 (5): 743–748.Foeldvari I., Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis // J. Rheumatol. — 2005; 32 (2): 362–365.Foeldvari I., Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis // J. Rheumatol. — 2005; 32 (2): 362–365.Chikanza I. C. Juvenile rheumatoid arthritis: therapeutic perspectives // Paediatr. Drugs. — 2002; 4 (5): 335–348.Chikanza I. C. Juvenile rheumatoid arthritis: therapeutic perspectives // Paediatr. Drugs. — 2002; 4 (5): 335–348.Johnsen V., Forre O., Haga H. J. et al. Combination therapy in rheumatoid arthritis // Tidsskr. Nor. Laegeforen. — 2003; 123 (11): 1511–1513.Johnsen V., Forre O., Haga H. J. et al. Combination therapy in rheumatoid arthritis // Tidsskr. Nor. Laegeforen. — 2003; 123 (11): 1511–1513.Dougados M., Combe B., Cantagrel A. et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components // Ann. Rheum. Dis. — 1999; 58: 220–225.Dougados M., Combe B., Cantagrel A. et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components // Ann. Rheum. Dis. — 1999; 58: 220–225.Garrood T., Scott D. L. Combination therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis // BioDrugs. — 2001; 15 (8): 543–561.Garrood T., Scott D. L. Combination therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis // BioDrugs. — 2001; 15 (8): 543–561.Tugwell P., Pincus T., Yocum D. et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis // N. Eng. J. Rheumatol. — 1995; 333 (3): 137–142.Tugwell P., Pincus T., Yocum D. et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis // N. Eng. J. Rheumatol. — 1995; 333 (3): 137–142.Marchesoni A., Battafarano N., Arreghini M. et al. Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone // Rheumatol. — 2003; 42 (12): 1545–1549.Marchesoni A., Battafarano N., Arreghini M. et al. Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone // Rheumatol. — 2003; 42 (12): 1545–1549.Ferraccioli G. F., Gremese E., Tomietto P. et al. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years // Rheumatol. — 2002; 41: 892–898.Ferraccioli G. F., Gremese E., Tomietto P. et al. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years // Rheumatol. — 2002; 41: 892–898.Gerards A. H., Landewe R. B. M., Prins A. P. A. et al. Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial // Ann. Rheum. Dis. — 2003; 62: 291–296.Gerards A. H., Landewe R. B. M., Prins A. P. A. et al. Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial // Ann. Rheum. Dis. — 2003; 62: 291–296.Sarzi-Puttini P., D'Ingianna E., Fumagalli M. et al. An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis // Rheumatol. Int. — 2005; 25 (1): 15–22.Sarzi-Puttini P., D'Ingianna E., Fumagalli M. et al. An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis // Rheumatol. Int. — 2005; 25 (1): 15–22.Ravelli A., Moretti C., Temporini F. et al. Combination therapy with methotrexate and cyclosporine A in juvenile idiopathic arthritis // Clin. Exp. Rheumatol. — 2002; 20 (4): 569–572.Ravelli A., Moretti C., Temporini F. et al. Combination therapy with methotrexate and cyclosporine A in juvenile idiopathic arthritis // Clin. Exp. Rheumatol. — 2002; 20 (4): 569–572.Алексеева Е. И., Валиева С. И., Бзарова Т. М. и др. Эффективность пульс-терапии метотрексатом у больных тяжелым системным ювенильным ревматоидным артритом // Вопросы современной педиатрии. — 2008; 7 (1): 29–34Алексеева Е. И., Валиева С. И., Бзарова Т. М. и др. Эффективность пульс-терапии метотрексатом у больных тяжелым системным ювенильным ревматоидным артритом // Вопросы современной педиатрии. — 2008; 7 (1): 29–34St. Clair E. W., van der Heijde D. M., Smolen J. S. et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial // Arthritis Rheum. — 2004; 11: 3432–3443.St. Clair E. W., van der Heijde D. M., Smolen J. S. et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial // Arthritis Rheum. — 2004; 11: 3432–3443.Van der Kooij S. M., Goekoop-Ruiterman Y. P. M., de VriesBouwstra J. K. et al. Clinical and radiological efficacy in fourth different treatment strategies in patients with early rheumatoid arthritis: 3-year follow-up of the BeSt Study // Ann. Rheum. Dis. — 2007; 66 (2): 91.Van der Kooij S. M., Goekoop-Ruiterman Y. P. M., de VriesBouwstra J. K. et al. Clinical and radiological efficacy in fourth different treatment strategies in patients with early rheumatoid arthritis: 3-year follow-up of the BeSt Study // Ann. Rheum. Dis. — 2007; 66 (2): 91.Van der Kooij S. M., Allaart C. F., de Vries-Bouwstra J. K. et al. Remission induction in Early Rheumatoid Arthritis with initial infliximab and methotrexate therapy: 4-year follow-up data of the disease course after infliximab discontinuation in the BeSt trial // Ann. Rheum. Dis. — 2007; 66 (2): 192.Van der Kooij S. M., Allaart C. F., de Vries-Bouwstra J. K. et al. Remission induction in Early Rheumatoid Arthritis with initial infliximab and methotrexate therapy: 4-year follow-up data of the disease course after infliximab discontinuation in the BeSt trial // Ann. Rheum. Dis. — 2007; 66 (2): 192.Van der Kooij S. M., Goekoop-Ruiterman Y. P. M., de VriesBouwstra J. K. et al. Initial versus delayed treatment with infliximab plus methotrexate in in patients with early rheumatoid arthritis: results from the BeSt Study // Ann. Rheum. Dis. — 2007; 66 (2): 53.Van der Kooij S. M., Goekoop-Ruiterman Y. P. M., de VriesBouwstra J. K. et al. Initial versus delayed treatment with infliximab plus methotrexate in in patients with early rheumatoid arthritis: results from the BeSt Study // Ann. Rheum. Dis. — 2007; 66 (2): 53.Breedveld F., Weisman M., Kavanaugh A. et al. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment // Arthritis Rheum. — 2006, 54: 26–37.Breedveld F., Weisman M., Kavanaugh A. et al. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment // Arthritis Rheum. — 2006, 54: 26–37.Van der Heijde D., Klareskog L., Rodriguez-Valverde V. et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis. two-year clinical and radiographic Results from the TEMPO Study, a double-blind, randomized trial // Arthritis Rheum. — 2006, 54: 1063–1074.Van der Heijde D., Klareskog L., Rodriguez-Valverde V. et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis. two-year clinical and radiographic Results from the TEMPO Study, a double-blind, randomized trial // Arthritis Rheum. — 2006, 54: 1063–1074.Maini R. N., Breedveld F. C., Kalden J. R. et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis // Arthritis Rheum. — 1998; 41: 1552–1563.Maini R. N., Breedveld F. C., Kalden J. R. et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis // Arthritis Rheum. — 1998; 41: 1552–1563.Lovell D. J., Giannini E. H., Reiff A. et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group // N. Engl. J. Med. — 2000; 342: 763–769.Lovell D. J., Giannini E. H., Reiff A. et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group // N. Engl. J. Med. — 2000; 342: 763–769.

The authors declare that there are no conflicts of interest present.